Fexofenadine in Pruritic Skin Disease
Phase 4
Completed
- Conditions
- Pruritus
- Registration Number
- NCT00261079
- Lead Sponsor
- Handok Inc.
- Brief Summary
Primary objective:
* To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease
Secondary objective:
* To evaluate patient's satisfaction of Allegra treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 435
Inclusion Criteria
- All patients diagnosed with atopic dermatitis, contact dermatitis
Exclusion Criteria
- Other skin disease except atopic dermatitis, contact dermatitis.
- Subjects taken steroid within 4 weeks and antihistamine within 1 week before screening day.
- Pruritus localized only head and face
- Subjects with severe hepatic, renal, heart dysfunction.
- Subjects with history of alcohol and drug abuse.
- Pregnant and lactating women.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The change of physician's assessment on pruritic score before and after 7-day treatment.
- Secondary Outcome Measures
Name Time Method Patient visual analogue scale change and Overall satisfaction.
Trial Locations
- Locations (1)
Handok
🇰🇷Seoul, Korea, Republic of